Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Myconostica presents data on Mycassay Pneumocystis

Myconostica, the UK based medical diagnostic company, has presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.

MycAssay Pneumocystis is a molecular diagnostic test specific to Pneumocystis jirovecii and is CE marked and Health Canada approved for diagnostic purposes on the real-time PCR thermocyclers in the market.

Myconostica said that the study demonstrated the sensitivity and specificity of the test as 93% and 91% respectively, when compared with final clinical diagnosis.

Myconostica chief business officer John Thornback said that MycAssay Pneumocystis is a robust, standardardised and easy to use assay, that delivers results within four hours. The study shows a high sensitivity and specificity for detection of the pathogen with a very high negative predictive value suggesting a possible role for the assay in ruling out the presence of this pathogen.